Compare MobilEye Global Inc (MBLY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs TransMedics Group Inc — how do they compare? MobilEye Global Inc trades at $8.8 (market cap $7.54B), while TransMedics Group Inc trades at $87.9 (market cap $3.10B). The key difference: MobilEye Global Inc is far larger — about 2.4× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| MBLY | TMDX | |
|---|---|---|
Market Cap | $7.54B | $3.10B |
Sector | Technology | Technology |
52-Week High | $15.54 | $150.42 |
52-Week Low | $6.56 | $61.99 |
Enterprise Value | $6.10B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global Inc. (MBLY) trades at $8.77, up 0.23% on the day, with a bullish technical signal driven by moving averages. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $0.19 surpassing expectations, but faces fundamental challenges with a net income margin of -201.49% in 2026. Recent news highlights CEO transition and expanded partnerships, such as the Stellantis ADAS supply deal announced July 21, 2026.
The outlook is mixed: analyst consensus is bullish with a $11.40 price target (61.54% buy ratings), but high valuation (EV/EBITDA 43.25) and profitability risks persist. Investment opportunity lies in autonomous driving growth, while key risks include leadership uncertainty and competitive pressures.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
